Loading…
Budgeting for Opioid Addiction Treatment Act
Legislative Progress
Introduced
February 7, 2019
Latest Action
February 7, 2019
Primary Sponsor
Joe Manchin, IIIIndependent(WV)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,086 other S bills in the 116th — cohort avg 30d
Budgeting for Opioid Addiction Treatment Act This bill imposes a one cent per milligram fee on the sale of active opioids by the manufacturer, producer, or importer. The fee excludes prescription drugs used exclusively for the treatment of opioid addiction as part of a medically assisted treatment effort. The Department of Health and Human Services (HHS) must establish a program to provide rebates or discounts to cancer and hospice patients to ensure that they do not pay the fee. Any increase in federal revenues from the fee after rebates and discounts are subtracted must be distributed to states under the Substance Abuse Prevention and Treatment Block Grant program. The states must use the funds exclusively for substance abuse (including opioid abuse) efforts in the states, including (1) specified treatment programs, and (2) the recruitment and training of substance use disorder professionals to work in rural and medically underserved communities. HHS must report to Congress on the impact of this bill on the retail cost of opioids and patient access to opioid medication, the effectiveness of the discount or rebate for cancer and hospice patients, how the funds are being used to improve substance abuse treatment efforts, and suggestions for improving access to opioids for cancer and hospice patients and substance abuse treatment efforts.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (1)
2020 · third_quarter · Taxation/Internal Revenue Code
S. 73, End Taxpayer Subsidies for Drug Ads Act, regarding all bio-pharmaceutical related provisions. S. 378/H.R. 1093, Stop Price Gouging Act, regarding all bio-pharmaceutical related provisions. S. 425, LifeBOAT Act, regarding all bio-pharmaceutical related provisions.
Client expense: $1,600,000 · Firm income: Not reported
Read twice and referred to the Committee on Finance.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
2020 · second_quarter · Taxation/Internal Revenue Code
S. 73, End Taxpayer Subsidies for Drug Ads Act, regarding all bio-pharmaceutical related provisions. S. 378/H.R. 1093, Stop Price Gouging Act, regarding all bio-pharmaceutical related provisions. S. 425, LifeBOAT Act, regarding all bio-pharmaceutical related provisions.
Client expense: $2,160,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
2020 · fourth_quarter · Taxation/Internal Revenue Code
S. 73, End Taxpayer Subsidies for Drug Ads Act, regarding all bio-pharmaceutical related provisions. S. 378/H.R. 1093, Stop Price Gouging Act, regarding all bio-pharmaceutical related provisions. S. 425, LifeBOAT Act, regarding all bio-pharmaceutical related provisions.
Client expense: $1,090,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
2020 · fourth_quarter · Taxation/Internal Revenue Code
S. 73, End Taxpayer Subsidies for Drug Ads Act, regarding all bio-pharmaceutical related provisions. S. 378/H.R. 1093, Stop Price Gouging Act, regarding all bio-pharmaceutical related provisions. S. 425, LifeBOAT Act, regarding all bio-pharmaceutical related provisions.
Client expense: $1,090,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
2020 · third_quarter · Taxation/Internal Revenue Code
S. 73, End Taxpayer Subsidies for Drug Ads Act, regarding all bio-pharmaceutical related provisions. S. 378/H.R. 1093, Stop Price Gouging Act, regarding all bio-pharmaceutical related provisions. S. 425, LifeBOAT Act, regarding all bio-pharmaceutical related provisions.
Client expense: $1,600,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
2020 · second_quarter · Taxation/Internal Revenue Code
S. 73, End Taxpayer Subsidies for Drug Ads Act, regarding all bio-pharmaceutical related provisions. S. 378/H.R. 1093, Stop Price Gouging Act, regarding all bio-pharmaceutical related provisions. S. 425, LifeBOAT Act, regarding all bio-pharmaceutical related provisions.
Client expense: $2,160,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
2020 · first_quarter · Taxation/Internal Revenue Code
S. 73, End Taxpayer Subsidies for Drug Ads Act, regarding all bio-pharmaceutical related provisions. S. 378/H.R. 1093, Stop Price Gouging Act, regarding all bio-pharmaceutical related provisions. S. 425, LifeBOAT Act, regarding all bio-pharmaceutical related provisions.
Client expense: $540,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
2019 · fourth_quarter · Taxation/Internal Revenue Code
S. 73, End Taxpayer Subsidies for Drug Ads Act, regarding all bio-pharmaceutical related provisions. S. 378/H.R. 1093, Stop Price Gouging Act, regarding all bio-pharmaceutical related provisions. S. 425, LifeBOAT Act, regarding all bio-pharmaceutical related provisions.
Client expense: $690,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
2019 · third_quarter · Taxation/Internal Revenue Code
S. 73, End Taxpayer Subsidies for Drug Ads Act, regarding all bio-pharmaceutical related provisions. S. 378/H.R. 1093, Stop Price Gouging Act, regarding all bio-pharmaceutical related provisions. S. 425, LifeBOAT Act, regarding all bio-pharmaceutical related provisions.
Client expense: $1,240,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
2019 · second_quarter · Taxation/Internal Revenue Code
S. 73, End Taxpayer Subsidies for Drug Ads Act, regarding all bio-pharmaceutical related provisions. S. 378/H.R. 1093, Stop Price Gouging Act, regarding all bio-pharmaceutical related provisions. S. 425, LifeBOAT Act, regarding all bio-pharmaceutical related provisions.
Client expense: $970,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
2019 · first_quarter · Taxation/Internal Revenue Code
S. 73, End Taxpayer Subsidies for Drug Ads Act, regarding all bio-pharmaceutical related provisions. S. 378/H.R. 1093, Stop Price Gouging Act, regarding all bio-pharmaceutical related provisions. S. 425, LifeBOAT Act, regarding all bio-pharmaceutical related provisions.
Client expense: $1,200,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
| Democratic |
| NH |
| Margaret Wood Hassan | Democratic | NH |
| Richard Blumenthal | Democratic | CT |
| Sheldon Whitehouse | Democratic | RI |
| Tammy Baldwin | Democratic | WI |
| Tina Smith | Democratic | MN |